sFlt-1PlGF Ratio as a Predictive Marker in Women with Suspected Preeclampsia: An Economic Evaluation from a Swiss Perspective

Joint Authors

Lapaire, Olav
Hodel, Markus
Blank, Patricia R.
Marty, Petra

Source

Disease Markers

Issue

Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-10, 10 p.

Publisher

Hindawi Publishing Corporation

Publication Date

2019-08-14

Country of Publication

Egypt

No. of Pages

10

Main Subjects

Diseases

Abstract EN

In Switzerland, 2.3% of pregnant women develop preeclampsia.

Quantification of the soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) ratio has shown a diagnostic value in the second and third trimesters of pregnancy, in particular in ruling out preeclampsia within one week.

We estimated the economic impact of implementing sFlt-1/PlGF ratio evaluation, in addition to the standard of care (SOC), for women with suspected preeclampsia from a Swiss healthcare system’s perspective.

A decision tree model was developed to estimate direct medical costs of diagnosis and management of a simulated cohort of Swiss pregnant women with suspected preeclampsia (median week of gestation: 32) until delivery.

The model compared SOC vs.

SOC plus sFlt-1/PlGF ratio, using clinical inputs from a large multicenter study (PROGNOSIS).

Resource use data and unit costs were obtained from hospital records and public sources.

The assumed cost for sFlt-1/PlGF evaluation was €141.

Input parameters were validated by clinical experts in Switzerland.

The model utilized a simulated cohort of 6084 pregnant women with suspected preeclampsia (representing 7% of all births in Switzerland in 2015, n=86,919).

In a SOC scenario, 36% of women were hospitalized, of whom 27% developed preeclampsia and remained hospitalized until birth.

In a sFlt-1/PlGF test scenario, 76% of women had a sFlt-1/PlGF ratio of ≤38 (2% hospitalized), 11% had a sFlt-1/PlGF ratio of >38-<85 (55% hospitalized), and 13% had a sFlt-1/PlGF ratio of ≥85 (65% hospitalized).

Total average costs/pregnant woman (including birth) were €10,925 vs.

€10,579 (sFlt-1/PlGF), and total costs were €66,469,362 vs.

€64,363,060 (sFlt-1/PlGF).

Implementation of sFlt-1/PlGF evaluation would potentially achieve annual savings of €2,105,064 (€346/patient), mainly due to reduction in unnecessary hospitalization.

sFlt-1/PlGF evaluation appears economically promising in predicting short-term absence of preeclampsia in Swiss practice.

Improved diagnostic accuracy and reduction in unnecessary hospitalization could lead to significant cost savings in the Swiss healthcare system.

American Psychological Association (APA)

Hodel, Markus& Blank, Patricia R.& Marty, Petra& Lapaire, Olav. 2019. sFlt-1PlGF Ratio as a Predictive Marker in Women with Suspected Preeclampsia: An Economic Evaluation from a Swiss Perspective. Disease Markers،Vol. 2019, no. 2019, pp.1-10.
https://search.emarefa.net/detail/BIM-1147167

Modern Language Association (MLA)

Hodel, Markus…[et al.]. sFlt-1PlGF Ratio as a Predictive Marker in Women with Suspected Preeclampsia: An Economic Evaluation from a Swiss Perspective. Disease Markers No. 2019 (2019), pp.1-10.
https://search.emarefa.net/detail/BIM-1147167

American Medical Association (AMA)

Hodel, Markus& Blank, Patricia R.& Marty, Petra& Lapaire, Olav. sFlt-1PlGF Ratio as a Predictive Marker in Women with Suspected Preeclampsia: An Economic Evaluation from a Swiss Perspective. Disease Markers. 2019. Vol. 2019, no. 2019, pp.1-10.
https://search.emarefa.net/detail/BIM-1147167

Data Type

Journal Articles

Language

English

Notes

Includes bibliographical references

Record ID

BIM-1147167